Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIJ821 single subcutaneous injection plus standard of care in treatment-resistant depression
jRCT2031220655Completed
- Sponsor
- Novartis
- Start
- May 2023
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of onfasprodil in treatment-resistant depression (TRD) and major depressive disorder (MDD) (4 arms), sponsored by Novartis. Primary endpoint: Change in MADRS total score at 24 hours. Started May 2023; status: completed.
02
Drugs
onfasprodil
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2031220655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220655.